Prescribing of anticancer drugs in renal impairment: why can’t we do better?
Explore this paper's citation graph
Summary
The dosing recommendations provided in the official product labeling (summary of product characteristics, SmPC) are compared with real-world prescribing practices for anticancer drugs in a German oncology center and three commonly used cytostatic agents, which are substantially eliminated renally are evaluated.
- Type
- letter
- Published
- 2018-01-06
- Cited by
- 2
- References
- 9
- Access
- Open access
- OpenAlex
- https://openalex.org/W2781761270
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8835465
Keywords
Medicine, Pharmacology, Internal medicine, Urology, Oncology
References
- Drug prescribing in renal failure: dosing guidelines for adults.
- Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?
- Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
- Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis
- Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
- Renal insufficiency and cancer treatments
- A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety
Cited by
Related papers
- MP-05.16 Hybrid LESS Prostatectomy for BPH: A Combined Technique
- MP-05.13 GreenLight HPS Laser Prostatectomy for Chronic Retention of Urine: A Safe and Efficacious Option
- MP-11.07: Results in patients who underwent prostate biopsy with PSA values 2,5 - 4 ng/ml
- POS-02.22: Neoadjuvant low-dose chemoradiotherapy against muscle-invasive bladder cancer: Possible improvement of survival and favorable local control for bladder-preserved patients
- POS-02.60: Independent predictors of bladder outlet obstruction associated with benign prostatic hyperplasia
- UP-01.10: Renal hypertension in patients 10 years after ESWL treatment for renal calculosis
- Survival Outcomes for Breast Cancer Patients with Liver Metastases: A Population-Based Study of 3,549 Patients
- MP-06.09: Ultrasound Assessment of Treatment Cavity Size after Greenlight Laser Prostatectomy vs. TURP